BALTIMORE, MD, United States
BALTIMORE, MD, United States

Time filter

Source Type

Patent
University of Maryland, Baltimore and Gliknik Inc. | Date: 2016-06-30

IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compounds efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.


Patent
Gliknik Inc. and University of Maryland, Baltimore | Date: 2014-03-20

IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compounds efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.


Patent
University of Maryland, Baltimore and Gliknik Inc. | Date: 2013-09-25

IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compounds efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.


Patent
University of Maryland, Baltimore and Gliknik Inc. | Date: 2016-06-08

IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compounds efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.


Patent
Gliknik Inc. and University of Maryland, Baltimore | Date: 2013-12-17

IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compounds efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.


Patent
Gliknik Inc. and University of Maryland, Baltimore | Date: 2013-09-20

IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compounds efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase II | Award Amount: 1.50M | Year: 2011

Background Information Rituxan and Herceptin are multi-billion dollar products that are useful in lymphoma and breast cancer. However, significant unmet medical need persists for certain populations such as recurrent indolent NHL, HER2 IHC 2+ patients, and treatment of patients with the FcgR3a 158 F/F polymorphism. This contract proposal is designed to: a) generate a novel anti-CD20 or anti-HER2 neu compound that will advance towards clinical trial and prove to have advantages over the currently marketed antibody compound, and b) establish a new therapeutic approach to cancer.


Patent
Gliknik Inc. | Date: 2016-09-07

The present invention relates to biologically active fusion proteins containing the IgG2 hinge as a multimerization domain capable of multimerizing proteins, peptides and small molecules which are active or more active in multimeric form; compositions comprising such fusion proteins; and methods of making and using such fusion proteins.


Patent
Gliknik Inc. | Date: 2013-01-28

The present invention relates to biologically active fusion proteins containing the IgG2 hinge as a multimerization domain capable of multimerizing proteins, peptides and small molecules which are active or more active in multimeric form; compositions comprising such fusion proteins; and methods of making and using such fusion proteins.


The current invention involves biologically active proteins termed stradobodies. The stradobodies have two or more domains that create stradobody multimers. The stradobodies have both antigen-binding capacity and the ability to bind Fc receptors (FcR), and are useful in the treatment and prevention of disease.

Loading Gliknik Inc. collaborators
Loading Gliknik Inc. collaborators